MARLBOROUGH, Mass.,
Sept. 7, 2016 /PRNewswire/ -- RXi
Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi
company developing innovative therapeutics that address significant
unmet medical needs, announced today it has been selected to
present at the Cavendish Global Health Impact Forum co-hosted with
the Arizona BioIndustry Association (AZBio) taking place
September 18-21, 2016 in Phoenix, Arizona. The purpose of the
Forum is to help family offices, foundations and impact investors
develop and implement their individual pro-social impact investing,
grant-giving, and philanthropy programs within health and the life
sciences. To accomplish this mission, the Forum showcases
presentations and panel discussions by leading family offices,
accomplished foundations, impact investors, research institutions,
nonprofit organizations, private-sector and publicly traded
companies engaged in developing innovations with the potential for
transformational impact on disease prevention, diagnosis and
treatment. A unique gathering of impact
investors, Cavendish Impact Forums are hosted by leading
institutions around the world and take place four times each
year.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
Michael Moffat, Cavendish
co-founder and Chairman explains, "The theme of our Phoenix Forum
is 'Innovation, Philanthropy and Impact Investing, Inspired for
Impact.' With the help of our expert advisors, we conduct a
global search of research institutions, private-sector and publicly
traded companies in order to identify organizations that meet the
required standard of excellence. The quality and originality
of RXi Pharmaceuticals research and scientific insights in the
development of novel RNAi-based therapeutics positions them well to
make a major contribution in the development of potential new
treatments for numerous diseases such as dermal and ocular
scarring, ALS and cancer."
"We are honored to be selected to present at this unique event,
and it is further recognition of our innovative approach using our
proprietary self-delivering RNAi compounds for the potential
treatment of numerous diseases. Our mission is to improve patients'
lives through the development of a new class of treatments based on
our novel platform," said Dr. Geert
Cauwenbergh, President and CEO of RXi Pharmaceuticals. "We
welcome the chance to interact with many of world's most
accomplished scientists, thought-leaders and generous philanthropic
individuals and families who are all dedicated to the common cause
of improving the health and lives of people around the world."
Cavendish Global consists of over 200 leading family offices,
foundations and impact investors from around the world with
combined assets of over $225 billion
who share a passion for pro-social endeavors within
health and the life sciences. The Cavendish Global Health Impact
Forum provides impact investors with a discrete, peer-to-peer
knowledge expansion and relationship building environment, combined
with the information and educational resources required by
foundations actively seeking to accelerate technological innovation
and health access through sustainable philanthropy, grant-making
and impact investing. The Forum is also an opportunity for
impact investors to champion and share information on projects and
organizations, which they are passionate about with other impact
investors from around the world.
About Cavendish Global
Cavendish Global provides family offices, foundations and impact
investors with a discrete, peer-to-peer knowledge expansion and
relationship building environment, combined with the innovative
resources required to help develop and implement their individual
pro-social impact investment and philanthropy programs within
health and the life sciences. Cavendish Global provides impact
investors with a number of innovative resources, which includes
Cavendish Health Impact Forums. A unique gathering of leading
impact investors, Cavendish Health Impact Forums take place four
times each year. More information may be found at:
http://cavendishglobal.com
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
clinical-stage RNAi company developing innovative therapeutics that
address significant unmet medical needs. Building on the
pioneering work of RXi's Scientific Advisory Board Chairman and
Nobel Laureate Dr. Craig Mello, our
discovery and clinical development programs are based on our
proprietary RNAi (sd-rxRNA) platform and Samcyprone™, a topical
immunomodulator. Our clinical development programs include RXI-109,
an sd-rxRNA for the treatment of dermal and ocular scarring, and
Samcyprone™ for the treatment of such disorders as warts, alopecia
areata, non-malignant skin tumors and cutaneous metastases of
melanoma. RXi's robust pipeline, coupled with an extensive
patent portfolio, provides for multiple product and business
development opportunities across a broad spectrum of therapeutic
areas. We are committed to being a partner of choice for academia,
small companies, and large multinationals. We welcome ideas and
proposals for strategic alliances, including in- and out-licensing
opportunities, to advance and further develop strategic areas of
interest. Additional information may be found on the Company's
website, www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™ and
our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
Cavendish Global
Gwen Snyder
Vice President, Member Services
Gwen.snyder@cavendishglobla.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-corporation-selected-to-present-at-cavendish-global-health-impact-forum-300323308.html
SOURCE RXi Pharmaceuticals Corporation